Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mercedeh Ghadessi

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Orphanet Journal of Rare Diseases|April 11, 2023
Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspectiveMercedeh Ghadessi, Junrui Di, Chenkun Wang, et al.
Orphanet Journal of Rare Diseases|March 14, 2020
A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)Mercedeh Ghadessi, Rui Tang, Joey Zhou, et al.
The Journal of Clinical Endocrinology and Metabolism|August 10, 2013
Whole-transcriptome profiling of thyroid nodules identifies expression-based signatures for accurate thyroid cancer diagnosisSam M Wiseman, Zaid Haddad, Blair Walker, et al.
Therapeutic Innovation & Regulatory Science|August 8, 2025
Insights on Clinical Development of Cell and Gene Therapy for Rare Diseases-by DahShu Innovative Design Scientific Working Group (IDSWG)Chenkun Wang, Junrui Di, Mercedeh Ghadessi, et al.
BJU International|March 13, 2015
Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrenceMohammed Alshalalfa, Anamaria Crisan, Ismael A Vergara, et al.
European Urology|April 30, 2015
Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk MenAshley E Ross, Kasra Yousefi, Elai Davicioni, et al.
Journal of the National Cancer Institute|October 26, 2014
Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancerAnirban P Mitra, Lucia L Lam, Mercedeh Ghadessi, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapyRobert B Den, Felix Y Feng, Timothy N Showalter, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2012
Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcomePaula J Hurley, Luigi Marchionni, Brian W Simons, et al.
Plos One|July 5, 2013
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomyNicholas Erho, Anamaria Crisan, Ismael A Vergara, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Orphanet Journal of Rare Diseases|April 11, 2023
Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspectiveMercedeh Ghadessi, Junrui Di, Chenkun Wang, et al.
Orphanet Journal of Rare Diseases|March 14, 2020
A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)Mercedeh Ghadessi, Rui Tang, Joey Zhou, et al.
The Journal of Clinical Endocrinology and Metabolism|August 10, 2013
Whole-transcriptome profiling of thyroid nodules identifies expression-based signatures for accurate thyroid cancer diagnosisSam M Wiseman, Zaid Haddad, Blair Walker, et al.
Therapeutic Innovation & Regulatory Science|August 8, 2025
Insights on Clinical Development of Cell and Gene Therapy for Rare Diseases-by DahShu Innovative Design Scientific Working Group (IDSWG)Chenkun Wang, Junrui Di, Mercedeh Ghadessi, et al.
BJU International|March 13, 2015
Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrenceMohammed Alshalalfa, Anamaria Crisan, Ismael A Vergara, et al.
European Urology|April 30, 2015
Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk MenAshley E Ross, Kasra Yousefi, Elai Davicioni, et al.
Journal of the National Cancer Institute|October 26, 2014
Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancerAnirban P Mitra, Lucia L Lam, Mercedeh Ghadessi, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapyRobert B Den, Felix Y Feng, Timothy N Showalter, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2012
Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcomePaula J Hurley, Luigi Marchionni, Brian W Simons, et al.
Plos One|July 5, 2013
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomyNicholas Erho, Anamaria Crisan, Ismael A Vergara, et al.
Pageof 3